Consideration on Nonclinical Evaluation for the Conduct of Human Clinical Trails and Marketing Authorization for New Anticancer Drugs

王海学,陈晓媛,钱思源,彭健
DOI: https://doi.org/10.3969/j.issn.1001-6821.2009.02.026
2009-01-01
Abstract:Nonclinical evaluation can be involved in the whole process of clinical trail and marketing application.International conference on harmonization(ICH) drafted a step 2 guidance(M3)with nonclinical evaluation for the conduct of human clinical trails and marketing authorization for pharmaceutics.As for anticancer drugs,ICH M3 indicated that,pharmaceuticals under development for indications in life threatening or serious diseases(e.g.,advanced cancer,) without current effective therapy might do as case-bycase approach.This article discussed the nonclinical evaluation consideration for oncology drugs,which will give some suggestions for new anticancer drug research and evaluation.
What problem does this paper attempt to address?